|
Published by: Global Markets Direct
Published: Feb. 28, 2011 - 103 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Osteoarthritis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Osteoarthritis
- Osteoarthritis Therapeutics under Development by Companies
- Osteoarthritis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Companies Involved in Osteoarthritis Therapeutics Development
- Alcon, Inc.
- Genzyme Corporation
- Johnson & Johnson
- AlphaRx, Inc.
- Sanofi-Aventis
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Taisho Pharmaceutical Co., Ltd.
- Acologix, Inc.
- Novartis AG
- Dong-A Pharmaceutical Co., Ltd.
- Glenmark Pharmaceuticals Ltd.
- Pfizer Inc.
- Optimer Pharmaceuticals, Inc.
- Menarini Group
- Geron Corporation
- Merck KGaA
- Bone Medical Limited
- Addex Pharmaceuticals
- IntelGenx Technologies Corp.
- Medivir AB
- NicOx SA
- Osteologix, Inc.
- Regeneron Pharmaceuticals, Inc.
- Unigene Laboratories, Inc.
- Green Cross Corporation
- Galapagos NV
- CrystalGenomics, Inc.
- Simcere Pharmaceutical Group
- AnaMar Medical AB
- Jenrin Discovery, Inc.
- IDEA AG
- Quigley Pharma, Inc.
- Amura Holdings Ltd.
- IMMD Inc.
- Grupo Uriach
- PLx Pharma Inc.
- TissueGene, Inc.
- Rottapharm SpA
- Nordic Bioscience a/s
- Logical Therapeutics, Inc.
- Omeros Corporation
- Iroko Pharmaceuticals, LLC
- Winston Pharmaceuticals, Inc.
- Phytomedics, Inc.
- Laboratoire Negma SAS
- Cellceutix Pharmaceuticals, Inc.
- Eurofarma
- Nucitec, S.A. de C.V.
- Mantecorp Industria Quimica e Farmaceutica Ltda
- Universities/Institutes Involved in Osteoarthritis Therapeutics Development
- Osteoarthritis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Late Stage Drug Profiles - Companies
- Arcoxia - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ART 44 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Civanex - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Diacerein - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Diractin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GCSB-5 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Glucosamine + Chondroitin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Glucosamine Sulfate + Chondroitin Sulfate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HZT-501 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Iguratimod - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- JNS013 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Joicela - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Kondrium - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Kondrium f - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LT-NS001 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Naproxcinod - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Naproxcinod - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SMC021 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Tanezumab + NSAIDs - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Late Stage Drug Profiles - Universities/Institutes
- Alendronate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Curcuma Domestica Extracts - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Derris Scandens Benth Extracts - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Dextrose - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Glucosamine + Chondroitin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Humira - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Hydrocortisone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Hydroxychloroquine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Hydroxychloroquine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Methotrexate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Platelet Rich Plasma - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Sodium Hyaluronate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Synvisc - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Discontinued Products
- Osteoarthritis - Featured News
- 1. Oct 06, 2010: CrystalGenomics Plans To Conduct Preclinical Research Project To Investigate Potential Anti-Tumor Effects Of CG100649 With MD Anderson Cancer Center
- 2. Oct 04, 2010: CrystalGenomics To Present Preliminary Results From Phase I Study Of CG100649 At Arrowhead Annual Pain Therapeutics Summit
- 3. Jul 22, 2010: NicOx Receives Complete Response Letter From FDA Related To NDA For Naproxcinod
- 4. Jul 20, 2010: Winston Receives Notice Of Compliance In Canada For CIVANEX For Treatment Of Osteoarthritis
- 5. Jul 13, 2010: Addex's ADX71943 Demonstrates Efficacy In Osteoarthritis Pain Model
- 6. Jul 07, 2010: Winston Laboratories Submits NDA For CIVANEX For Treatment Of Osteoarthritis
- 7. Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
- 8. Jun 17, 2010: Adolor Announces Results From Phase IIa Study Of ADL5747 In Patients With Osteoarthritis
- 9. Jun 17, 2010: Adolor Announces Results From Phase IIa Study Of ADL5859 In Patients With Osteoarthritis
- 10. May 26, 2010: Horizon Pharma, Inc. Announces FDA Acceptance Of HZT-501 New Drug Application For Filing
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Osteoarthritis, 2011
- Products under Development for Osteoarthritis - Comparative Analysis, 2011
- Comparative Analysis by Late Stage Development, 2011
- Comparative Analysis by Mid Clinical Stage Development, 2011
- Comparative Analysis by Early Clinical Stage Development, 2011
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
- Alcon, Inc., 2011
- Genzyme Corporation, 2011
- Johnson & Johnson, 2011
- AlphaRx, Inc., 2011
- Sanofi-Aventis, 2011
- Eli Lilly and Company, 2011
- GlaxoSmithKline plc, 2011
- Merck & Co., Inc., 2011
- Taisho Pharmaceutical Co., Ltd., 2011
- Acologix, Inc., 2011
- Novartis AG, 2011
- Dong-A Pharmaceutical Co., Ltd., 2011
- Glenmark Pharmaceuticals Ltd., 2011
- Pfizer Inc., 2011
- Optimer Pharmaceuticals, Inc., 2011
- Menarini Group, 2011
- Geron Corporation, 2011
- Merck KGaA, 2011
- Bone Medical Limited, 2011
- Addex Pharmaceuticals, 2011
- IntelGenx Technologies Corp., 2011
- Medivir AB, 2011
- NicOx SA, 2011
- Osteologix, Inc., 2011
- Regeneron Pharmaceuticals, Inc., 2011
- Unigene Laboratories, Inc., 2011
- Green Cross Corporation, 2011
- Galapagos NV, 2011
- CrystalGenomics, Inc., 2011
- Simcere Pharmaceutical Group, 2011
- AnaMar Medical AB, 2011
- Jenrin Discovery, Inc., 2011
- IDEA AG, 2011
- Quigley Pharma, Inc., 2011
- Amura Holdings Ltd., 2011
- IMMD Inc., 2011
- Grupo Uriach, 2011
- PLx Pharma Inc., 2011
- TissueGene, Inc., 2011
- Rottapharm SpA, 2011
- Nordic Bioscience a/s, 2011
- Logical Therapeutics, Inc., 2011
- Omeros Corporation, 2011
- Iroko Pharmaceuticals, LLC, 2011
- Winston Pharmaceuticals, Inc., 2011
- Phytomedics, Inc., 2011
- Laboratoire Negma SAS, 2011
- Cellceutix Pharmaceuticals, Inc., 2011
- Eurofarma, 2011
- Nucitec, S.A. de C.V., 2011
- Mantecorp Industria Quimica e Farmaceutica Ltda, 2011
- Assessment by Monotherapy Products, 2011
- Assessment by Combination Products
- Assessment by Stage and Route of Administration, 2011
- Assessment by Molecule Type, 2011
- Discontinued Products
- List of Figures
- Number of Products under Development for Osteoarthritis, 2011
- Products under Development for Osteoarthritis - Comparative Analysis, 2011
- Products under Development by Companies, 2011
- Products under Investigation by Universities/Institutes, 2011
- Late Stage Products, 2011
- Mid Clinical Stage Products, 2011
- Early Clinical Stage Products, 2011
- Discovery and Pre-Clinical Stage Products, 2011
- Assessment by Monotherapy Products, 2011
- Assessment by Combination Products, 2011
- Assessment by Route of Administration, 2011
- Assessment by Stage and Route of Administration, 2011
- Assessment by Molecule Type, 2011
- Assessment by Stage and Molecule Type, 2011
AbstractOsteoarthritis - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, Q1 2011', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. 'Osteoarthritis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope - A snapshot of the global therapeutic scenario for Osteoarthritis.
- A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteoarthritis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Osteoarthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Osteoarthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
